Stem Cell Research (Aug 2023)

Correction of a deleterious TBX5 mutation in an induced pluripotent stem cell line (DHMi004-A-1) using a completely plasmid-free CRISPR/Cas 9 approach

  • Harald Lahm,
  • Elda Dzilic,
  • Irina Neb,
  • Stefanie A. Doppler,
  • Stephanie Schneider,
  • Rüdiger Lange,
  • Markus Krane,
  • Martina Dreßen

Journal volume & issue
Vol. 70
p. 103126

Abstract

Read online

TBX5 is a transcription factor which plays an essential role at different checkpoints during cardiac differentiation. However, regulatory pathways affected by TBX5 still remain ill-defined. We have applied the CRISPR/Cas9 technology using a completely plasmid-free approach to correct a heterozygous causative “loss-of function” TBX5 mutation in an iPSC line (DHMi004-A), that has been established from a patient suffering from Holt-Oram syndrome (HOS). This isogenic iPSC line, DHMi004-A-1, represents a powerful in vitro tool to dissect the regulatory pathways affected by TBX5 in HOS.